RespireRx Pharmaceuticals Inc (RSPI)

[food4thought]

Gfp can answer better to this, but my take is that as patents expire and neurological advancements pass us by, our company becomes worth less, not worthless, until they can prove some sort of efficacy in existing compounds. There have been and currently are running trials for different modalities using the ampakines compounds, most recently and notably CX-717 for reversing respiratory depression, where they saw positive results reversing opioid induced RD in rats.

And then there exists the whole FDA rejection post mortem toxicity issue with CX717 in the monkey trial a decade ago that blew up my net worth. So I think they’re still trying to prove it’s safety at high doses.